Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nokia Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.23 (market cap $29.97B), while Nokia Corp trades at $10.67 (market cap $58.06B). The key difference: Nokia Corp is the larger of the two by market cap, and Nokia Corp pays a 1.58% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NOK | |
|---|---|---|
Market Cap | $29.97B | $58.06B |
Sector | Health | Technology |
52-Week High | $491.22 | $16.83 |
52-Week Low | $205.48 | $4.13 |
Enterprise Value | $27.93B | $56.02B |
Dividend Yield | — | 1.58% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
